{"id":"NCT00571649","sponsor":"Bayer","briefTitle":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","officialTitle":"Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-08","completion":"2010-11","firstPosted":"2007-12-12","resultsPosted":"2012-06-27","lastUpdate":"2016-09-15"},"enrollment":8101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Enoxaparin","otherNames":[]},{"type":"DRUG","name":"Rivaroxaban placebo","otherNames":[]},{"type":"DRUG","name":"Enoxaparin placebo","otherNames":[]}],"arms":[{"label":"Rivaroxaban (Xarelto, BAY59-7939)","type":"EXPERIMENTAL"},{"label":"Enoxaparin","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.","primaryOutcome":{"measure":"Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days","timeFrame":"Up to Day 35 + 6 days","effectByArm":[{"arm":"Rivaroxaban (Xarelto, BAY59-7939)","deltaMin":4.4,"sd":null},{"arm":"Enoxaparin","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0211"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":676,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Indonesia","Israel","Italy","Japan","Latvia","Lithuania","Luxembourg","Malaysia","Mexico","Netherlands","New Zealand","Norway","Pakistan","Peru","Poland","Portugal","Romania","Russia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["21359646","23388003","22863355","24970782","24460645","35389229","34755519","33586478","32657973","31975354","28762617","28617144"],"seeAlso":["http://www.clinicaltrialsregister.eu"]},"adverseEventsSummary":{"seriousAny":{"events":1034,"n":3997},"commonTop":["Constipation","Diarrhoea","Nausea","Headache","Hypokalaemia"]}}